FDA approves new treatment for FOP

Total new heterotopic ossification volume decreased with treatment and increased with placebo at week 24.

1

The FDA approved zilurgisertib (Atebrioz) for reducing heterotopic ossification in patients with fibrodysplasia ossificans progressiva.
2

Fibrodysplasia ossificans progressiva is a rare genetic disease caused by a mutation in the activin A receptor-type 1.
3

Zilurgisertib was evaluated in a trial with 63 patients, showing a mean decline in ossification volume compared to placebo.
4

Common adverse effects of zilurgisertib include headache, joint pain, and upper respiratory tract infections.
5

Zilurgisertib received fast track, priority review, and orphan drug designations from the FDA for its indication.

1